Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Multi-omics Study of Solitary Bone Plasmacytomas to Elucidate their Pathogenesis and Risk of Progression to Multiple Myeloma
Rochester, Minn.
The purpose of this study is to obtain archived residual formalin-fixed-paraffin-embedded tissue from diagnostic biopsies of solitary bone plasmacytomas for cytogenetic and proteomic testing followed by correlations to their radiographic and clinical features. Clinical, radiographic, and laboratory features of solitary bone plasmacytomas will be evaluated to determine if they can define patients at risk of rapidly progressing to multiple myeloma.
-
A Phase 1b Trial Of Teclistamab In Combination With Iberdomide For Relapsed/Refractory Multiple Myeloma
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating hard-to-treat multiple myeloma. Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with multiple myeloma.
-
A Pilot Study of 13Carbon-based Deep Labelling of Bone Marrow Cells to Map their Utilization of Extracellular Metabolites
Rochester, Minn.
The purpose of this studyis to evaluate differences in the amount of extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma
cells (pPCs).
-
Assessment of Metabolites and Extracellular Vesicles in Biofluids from Patients with Plasma Cell Disorders
Rochester, Minn.
The purpose of this study is to collect peripheral blood samples and urine samples from patients with plasma cell disorders for metabolite and extracellular vesicle assessments.
-
In vivo and Ex vivo methodologies of assessing the utilization of extracellular metabolites of normal bone marrow plasma cells from healthy subjects by stable isotope resolved metabolomics.
Rochester, Minn.
This study will establish in vivo and ex vivo methodologies of assessing the utilization of extracellular nutrients by normal bone marrow plasma cells from healthy subjects.
Closed for Enrollment
-
(ECTx) MC1811: An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Rochester, Minn.,
Jacksonville, Fla.
The purpose of this study is to assess the maximum tolerated dose (MTD) of administering metformin in combination with nelfinavir in patients with relapsed/refractory multiple myeloma.
-
A Phase 1/2 Open-Label Multi-Center Study To Characterize The Safety And Tolerability Of CFT7455 In Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma Or Multiple Myeloma
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone.
-
A real Life Experience on Patient-Reported Quality of Life Outcomes in Subjects with Newly Diagnosed or Relapsed Refractory Multiple Myeloma Treated with Daratumumab Regimens
Rochester, Minn.
The primary purpose of this study is to evaluate patient-reported health-related quality of life outcomes in subjects with Relapsed/Refractory Multiple Myeloma (RRMM) treated with daratumumab-based regimens in a real life setting.
-
CC-92480-MM-002 A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Rochester, Minn.
The purpose of this study is to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary effectiveness of CC-92480 in combination with standard treatments.
-
Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma
Rochester, Minn.
The utilization of glutamine by the bone marrow plasma cells in MGUS and MM will be compared between each other after infusion of 13-carbon labelled glutamine.
-
MC210809, Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The primary goal of this study is to determine response rates (>=PR) of prospectively treated MM patients with one cycle of therapy containing a combination of an immunomodulator and dexamethasone.
-
ORIC-533-01, An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
Rochester, Minn.
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
-
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor Telaglenastat (CB-839) HCl in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Rochester, Minn.
The purpose of this study is to determine the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.
.